Galectin Therapeutics
GALT
GALT
83 hedge funds and large institutions have $43.7M invested in Galectin Therapeutics in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 25 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
less ownership
Funds ownership: →
1% less funds holding
Funds holding: 84 → 83 (-1)
16% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 25
Holders
83
Holding in Top 10
–
Calls
$1.28M
Puts
$728K
Top Buyers
| 1 | +$2.22M | |
| 2 | +$1.07M | |
| 3 | +$369K | |
| 4 |
VCM
Vivaldi Capital Management
Chicago,
Illinois
|
+$353K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$269K |
Top Sellers
| 1 | -$3.11M | |
| 2 | -$577K | |
| 3 | -$399K | |
| 4 |
SIA
Soltis Investment Advisors
St. George,
Utah
|
-$297K |
| 5 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$267K |
